Possible involvement of AT2 receptor dysfunction in age-related gender difference in vascular remodeling

Journal of the American Society of Hypertension

Volumn 5, Issue 2, 2011, Pages 76-84

  Okumura, Midori ^a   Iwai, Masaru ^a   Nakaoka, Hirotomo ^a   Sone, Hisako ^a   Kanno, Harumi ^a   Senba, Izumi ^a   Ito, Masaharu ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

aging; Angiotensin receptor; estrogen

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; CHEMOKINE; ESTRADIOL; ESTROGEN; SUPEROXIDE; MESSENGER RNA;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DNA SYNTHESIS; ESTROGEN BLOOD LEVEL; FEMALE; FEMORAL ARTERY; MALE; MOUSE; NEOINTIMA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEX DIFFERENCE; VASCULARIZATION; AGE; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; INTIMA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

AGE FACTORS; ANIMALS; ESTRADIOL; FEMALE; FEMORAL ARTERY; MALE; MICE; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; NEOINTIMA; RECEPTOR, ANGIOTENSIN, TYPE 2; RNA, MESSENGER; SEX FACTORS; SUPEROXIDES; TUNICA INTIMA;

EID: 79952722445     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2011.01.007     Document Type: Article

References (32)

1. Taler SJ. Hypertension in women. Curr Hypertens Rep 2009;11:23-8.
2. Palacios S. Advances in hormone replacement therapy: making the menopause manageable. BMC Womens Health 2008;8:22.
3. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986;111:383-90. (Pubitemid 16107280)
4. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-62.
5. Rossouw JE. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res 2002;53:550-7. (Pubitemid 34175247)
6. Ferreira AJ, Santos RA, Bradford CN, Mecca AP, Sumners C, Katovich MJ, et al. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension 2010;55:207-13.
7. Okumura M, Iwai M, Ide A, Mogi M, Ito M, Horiuchi M. Sex difference in vascular injury and the vasoprotective effect of valsartan are related to differential AT2 receptor expression. Hypertension 2005;46:577-83. (Pubitemid 41376840)
8. 2 receptor expression and signaling. Physiol Genom 2000;2:13-20.
9. Wu L, Iwai M, Nakagami H, Li Z, Chen R, Suzuki J, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 2001;104:2716-21. (Pubitemid 33108140)
10. Wu L, Iwai M, Nakagami H, Chen R, Suzuki J, Akishita M, et al. Effect of angiotensin II type 1 receptor blockade on cardiac remodeling in angiotensin II type 2 receptor null mice. Arterioscler Thromb Vasc Biol 2002;22:49-54. (Pubitemid 34076231)
11. 2 receptors in neointima formation. Circulation 2002;106:847-53.
12. Csiszar A, Wang M, Lakatta EG, Ungvari ZI. Inflammation and endothelial dysfunction during aging: role of NFkB. J Appl Physiol 2008;105:1333-41.
13. Oudot A, Martin C, Busseuil D, Vergely C, Demaison L, Rochette L. NADPH oxidases are in part responsible for increased cardiovascular superoxide production during aging. Free Radical Biol Med 2006;40:2214-22. (Pubitemid 43922397)
14. Basso N, Paglia N, Stella I, de Cavanagh EM, Ferder L, del Rosario Lores Arnaiz M, et al. Protective effect of the inhibition of the renin-angiotensin- system on aging. Regul Pept 2005;128:247-52. (Pubitemid 40544840)
15. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995;377:744-7.
16. Tsuda M, Iwai M, Li J-M, Li H-S, Min L-J, Ide A, et al. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 2005;45:1-7.
17. 1 receptor blocker on neointima formation. Hypertension 2002;40:451-7.
18. Szocs K, Lassegue B, Sorescu D, Hilenski LL, Valppu L, Couse TL, et al. Upregulation of nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol. 2002;22:21-7. (Pubitemid 34076227)
19. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999;33:613-21. (Pubitemid 29091636)
20. de Gasparo M, Catt KJ, Inagami T, Wright TW, Unger T. International Union of Pharmacology. XX III. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-72.
21. Takeda-Matsubara Y, Nakagami H, Iwai M, Cui TX, Shiuchi T, Akishita M, et al. Estrogen activates phosphatases and antagonizes growth-promoting effects of angiotensin II. Hypertension 2002;39:41-5. (Pubitemid 34098086)
22. 2 in the rat. Regul Pept 2005;124:7-17.
23. Han HS, Yu E, Song JY, Park JY, Jang SJ, Choi J. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression. Mol Cancer Res. 2009;7:713-23.
24. Sheng MH, Amoui M, Stiffel V, Srivastava AK, Wergedal JE, Lau KH. Targeted transgenic expression of an osteoclastic transmembrane protein-tyrosine phosphatase in cells of osteoclastic lineage increases bone resorption and bone loss in male young adult mice. J Biol Chem. 2009;284:11531-45.
25. Simpkins JW, Yi KD, Yang SH. Role of protein phosphatases and mitochondria in the neuroprotective effects of estrogens. Front Neuroendocrinol 2009;30:93-105.
26. Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, et al. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004;43:263-9. (Pubitemid 38174185)
27. Oshita A, Iwai M, Chen R, Ide A, Okumura M, Fukunaga S, et al. Attenuation of inflammatory vascular remodeling by angiotensin II type 1 receptor-associated protein. Hypertension 2006;48:671-6. (Pubitemid 44843871)
28. Zhang L, Kosaka H. Sex-specific acute effect of estrogen on endothelium-derived contracting factor in the renal artery of hypertensive Dahl rats. J Hypertens 2002;20:237-46. (Pubitemid 34913788)
29. Zhang L, Fujii S, Kosaka H. Effect of oestrogen on reactive oxygen species production in the aortas of ovariectomized Dahl salt-sensitive rats. J Hypertens 2007;25:407-14. (Pubitemid 46071939)
30. Rosano GM, Vitale C, Lello S. Postmenopausal hormone therapy: lessons from observational and randomized studies. Endocrine 2004;24:251-4. (Pubitemid 41271157)
31. Yeap BB. Androgens and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2010;17:269-76.
32. 2 receptor research and therapeutic potential. J Renin Angiotensin Aldosterone Syst 2010;11:75-7.